Decent day in the market but biotechs did not seem to participate to the same extent. Of course, I do not have much time to follow the market on Tuesday but today seemed more like a consolidation day for biotechs than a follow through. There was a decent amount of red on my screen with […]
September 9- EOD
Some interesting news today and generally a positive market environment, although some of the recent high fliers seemed to take most of the day off. That is not completely surprising to see a pause in the moves. 1. BIOD was the stock of the weekend (and morning) given that they released what was originally argued […]
September 6- EOD
The week ended with some interesting action and volatility over Syria news. The markets appear jumpy but note that the sell off was over the words of Putin. I think a limited American led strike is basically accepted and priced in but the key will be the response. If Syria (and Russia/Iran) accept it and […]
September 6- EOD
The week ended with some interesting action and volatility over Syria news. The markets appear jumpy but note that the sell off was over the words of Putin. I think a limited American led strike is basically accepted and priced in but the key will be the response. If Syria (and Russia/Iran) accept it and […]
September 6- EOD
The week ended with some interesting action and volatility over Syria news. The markets appear jumpy but note that the sell off was over the words of Putin. I think a limited American led strike is basically accepted and priced in but the key will be the response. If Syria (and Russia/Iran) accept it and […]
September 5- EOD
As I noted before, Tuesday and Thursday will likely be shorter updates given my schedule but there is some important news that came out for some companies that I want to touch on. The market still seems to be looking for a direction but in general it seems like sentiment is improving. Certainly something we […]
September 4- EOD
There was some nice action in biotech land today despite not being particularly busy in terms of news. There was some interesting stock specific action and the sector was a mixed bag. Stocks without specific news tended to underperform but not universally so. The next couple of months will be interesting as volume will likely […]
September 3- EOD
I am going to try and cover what was a fairly busy day in biotech land but Tuesday and Thursday will necessarily be shorter than usual. The semester has started again and I spend most of Tuesday and Thursday teaching, which does not provide as much time to write notes but I will still provide […]
August 30- EOD
Well, perhaps this is the last time I will write this for awhile but a slow day in the market and news front. I guess it makes sense as the last day of trading before the long Labor Day weekend but still not a lot to talk about at all. The only notable action was […]
August 29- EOD
We got a trickle of some interesting biotech news but still nothing dramatic. I suspect that the pace will increase in September as the summer ends and the fall healthcare conference season begins. 1. PCYC announced the acceptance of the NDA for previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia (CLL)/small […]
August 28- EOD
Again, it is a quite day in the biotech realm as the market essentially treads water waiting for the strike on Syria before deciding on its next direction. The market was strong early on and then seemed to fade alter in the day and for the most part it seems that biotechs either followed the […]
August 27- EOD
I have bemoaned about slow days before but very little biotech news today. I will do some more macro Syria coverage and some tidbits from the biotech world. That being said, I think the market is heading into a time that will be driven more by macro issues than stock specific fundamentals. 1. It seems […]
August 26- EOD
The week is off to a good start with the end of the ONXX/AMGN saga and some strong moves in biotech land. There is not a lot of stock specific stories, so this is mainly going to focus on some macro issues both within biotech land and outside. 1. I want to start with the […]
August 22- EOD
A quiet day after the relatively interesting data release of INCY yesterday. Of course, it was forced quiet as the market broke for most of the day. There is really not much new to talk about outside of some positive sentiment in the sector (see the ONXX/AMGN discussion below). Outside of that it is more […]
August 21- Midday
There was certainly some interesting news today with INCY and I wanted to spend time going through the results as they actually raise as many questions as answers. I also wanted to put out my EOD early (so there will not be one after the market closes) in case some of you were interested in […]
August 20-EOD
There was really nothing special on the news front today but I guess we were getting a little spoiled with the VICL, MNKD, and GTXI data all coming out in the past week or so. The dramas are the same in terms of biotech valuations, what is happening with ONXX and AMGN, and so on. […]
August 19- EOD
Somewhat of a decent start to the week but unfortunately it appears like more of the same in term of general biotech sentiment and news flow. There are a couple of interesting notes but nothing that is significant enough to change the sentiment. 1. The biggest individual mover today was GTXI as it announced the […]
August 16- EOD (kind of)
This is a Friday in August and so it is not surprising that it was light on the news front as well as it being another low volume chop fest. That being said biotechs seemed to be getting their footing more so than earlier in the week but it is still very difficult to tell […]
August 15- EOD
Markets started off weak again and biotechs followed down. Outside of the conference call from MNKD there was not much news in terms of data. Perhaps it is this lack of near term catalysts coupled with running too far too fast that is dragging biotechs. Regardless, it is more of the same. 1. The news […]
August 14- EOD
The big news of the morning at least was the MNKD data and all we need now is GTXI to complete the trifecta. The markets were a little better in that biotechs did not seem as weak, although I would not say are quite turning the corner. In fact, as the market turned down it […]
